Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of VK5211 in hip fracture patients
2016-000377-20Phase 2Completed
- Sponsor
- Viking Therapeutics
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hip fracture comparing VK5211 with Placebo (2 arms). Primary endpoint: Primary efficacy endpoint. Started Apr 2016; status: completed.
02
Drugs
Ligandrol
03
Conditions
hip fracture
Beyond the preview
Go deeper on 2016-000377-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000377-20.